Data will be presented at proffered paper session: NSCLC, locally advanced and metastatic
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a development stage
biopharmaceutical company, announced that data from a Phase II clinical
trial of its investigational drug PB272 (neratinib) for the treatment of
patients with non-small cell lung cancer (NSCLC) that has a HER2
mutation will be presented as a late-breaking oral presentation at the
European Society for Medical Oncology (ESMO) 2014 Congress, September
26-30, in Madrid, Spain. Themore...